kidney disease glp 1 GLP-1 receptor agonist versus DPP-4 inhibitor and and cardiovascular outcomes in clinical practice in type-2 diabetes GLP-1 Agonism for Kidney Transplant

Thats still a solid number, especially when appetite is tiny

International Journal of Impotence Research, 16(1), 51-59

KEY FINDINGS BAR (8 stat cards) STAT 1: $150B - projected global category size by 2030 STAT 2: ~58% - of total category AI citation share captured by six pharma brands STAT 3: 2 - companies (Novo Nordisk and Eli Lilly) own nearly 100% of GLP-1 citations STAT 4: ~13% - AI Overview trigger rate on health queries, highest of any consumer category STAT 5: 60-70% - share of "best diet app" AI answers citing MyFitnessPal first STAT 6: 200M+ - registered MyFitnessPal user base, the informational moat behind its citation lock STAT 7: 60+ - consumer prompts tracked across ChatGPT, Claude, Perplexity, and Google AI Overviews to build the index STAT 8: 25 - brands ranked, with the remaining ~11% citation share split across ranks 16-25 and unranked brands THE TOP 15 BY AI CITATION SHARE Estimated share of citations across 60+ weight-loss-related consumer prompts run through ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026

President Donald Trump promised from the White House Thursday that Novo Nordisks Ozempic will cost about $150 when he and Centers for Medicare & Medicaid Services Administrator Mehmet Oz are done negotiating with the company

Glycine helps redirect that search toward fat stores instead

Data availability The dataset generated and analyzed during the current study are available from the corresponding author on reasonable request